Amyloid β-protein (Aβ) accumulation in the putamen and mammillary body during aging and in Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 4, 1998, Pages 343-352

  Nakabayashi, Jun ^a,c   Yoshimura, Masahiro ^b   Morishima Kawashima, Maho ^a   Funato, Hiromasa ^a   Miyakawa, Taihei ^c   Yamazaki, Tsuneo ^a   Ihara, Yasuo ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Medical Examiner's Office   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Aging; Alzheimer disease; Amyloid protein; Mammillary body; Putamen

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MAMMILLARY BODY; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE DIAGNOSIS;

EID: 0031895715     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199804000-00007     Document Type: Article

References (43)

1. Shinkai Y, Yoshimura M, Ito Y, et al. Amyloid β-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels. Ann Neurol 1995;38:421-28
2. Hamano T, Yoshimura M, Yamazaki T, et al. Amyloid β-protein (Aβ) accumulation in the leptomeninges during aging and in Alzheimer disease. J Neuropathol Exp Neurol 1997;56:922-32
3. Shinkai Y, Yoshimura M, Morishima-Kawashima M, et al. Amyloid β-protein (Aβ) deposition in the leptomeninges and cerebral cortex. Ann Neurol 1997;42:899-908
4. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ-monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994;13:45-53
5. Iwatsubo T, Mann DMA, Odaka A, Suzuki N, Ihara Y. Amyloid β-protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down's syndrome. Ann Neurol 1995;37:294-99
6. Oyama F, Shimada H, Oyama R, Titani K, Ihara Y. Differential expression of β amyloid protein precursor (APP) and tau mRNA in the aged human brain: Individual variability and correlation between APP-751 and four-repeat tau. J Neuropathol Exp Neurol 1991;50:560-78
7. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
8. Suenaga T, Hirano A, Llena J E Yen S-H, Dickson D W. Modified Bielschowsky stain and imnumohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol 1990;80:280-86
9. Braak H, Braak E. Alzheimer's disease: Striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 1990;49:215-24
10. Tierney MC, Fisher H, Lewis AJ. The NICDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: Clinicopathological study of 57 cases. Neurology 1988;38:356-64
11. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
12. Suzuki N, Cheung TT, Cai X-D, et al. An increased percentage of long amyloid β-protein is secreted by familial amyloid β-protein precursor (βAPP717) mutants. Science 1994;264:1336-40
13. Asami-Odaka A, Ishibashi Y, Kikuchi T, Kitada C, Suzuki N. Long amyloid β-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry 1995;34:10272-78
14. Tamaoka A, Odaka A, Ishibashi Y, et al. APP 717 missense mutation affects the ratio of amyloid βprotein species (Aβ1-42(43) and Aβ1-40) in familial Alzheimer's disease brain. J Biol Chem 1995;269:32721-24
15. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): A possible form of preamyloid in Alzheimer's disease. Nature Med 1995;1:1062-66
16. Ida N, Hartman T, Pantel J, et al. Analysis of heterogenous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996;271:22908-14
17. Nordstedt C, Naslund J, Tjernberg LO, Karlstrom AR, Thyberg J, Terenius L. The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils. J Biol Chem 1994;269:30773-76
18. Gupta-Bansal R, Frederickson RC, Brunden KR. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 1995;270:18666-71
19. Shin RW, Ogino K, Kondo A, et al. Amyloid β-protein (Aß) 1-40 but not Aβ 1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J Neurosci 1997;17:8187-93
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-48
21. Ueki A, Kawano M, Namba Y, Kawasaki M, Ikeda K. A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. Neurosci Lett 1993;163:16-18
22. Yoshizawa T, Yamakawa-Kobayashi K, Komatsuzaki Y, et al. Dose-dependent association of apolipoprotein E allele e4 with late-onset, sporadic Alzheimer's disease. Ann Neural 1994;36:656-59
23. Schägger H, Jagow GV. Tricine-sodium dodecyl sulfatepolyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 1987;166:368-79
24. Harigaya Y, Shoji M, Kawarabayashi T, et al. Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophys Res Commun 1995;211:1015-22
25. Roher AE, Chancy MO, Kuo Y-M, et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996;271:20631-35
26. Gearing M, Wilson RW Unger ER, et al. Amyloid precursor protein (APP) in the striatum in Alzheimer's disease: An immunohistochemical study. J Neuropathol Exp Neurol 1993;52:22-30
27. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by β protein immunostain. Acta Neuropathol 1989;77:314-19
28. Gearing M, Schneider JA, Robbins RS, et al. Regional variation in the distribution of apolipoprotein E and Aβ in Alzheimer's disease. J Neuropathol Exp Neurol 1995;54:833-41
29. Oyanagi K, Takahashi H, Wakabayashi K, Ikuta F. Correlative decrease of large neurons in the neostriatum and basal nucleus of Meynert in Alzheimer's disease. Brain Res 1989;504:354-57
30. Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to β-amyloid identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 1994;667:138-42
31. Joachim CL, Duffy LK, Morris JH, Selkoe DJ. Protein chemical and immunocytochemical studies of meningovascular β-amyloid protein in Alzheimer's disease and normal aging. Brain Res 1988;474:100-11
32. Kang J, Lemaire H-G, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-36
33. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 1992;267:17082-86
34. Roher AE, Lowenson JD, Clarke S, et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993a;268:3072-83
35. Roher AE, Lowenson JD, Clarke S, et al. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993b;90:10836-40
36. Mann DM, Iwatsubo T. Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid β protein (Aβ) only in the form of Aβ42(43). Neurodegeneration 1996;5:115-20
37. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. Soluble amyloid Aβ-(1-40) exists as a stable dimer at low concentrations. J Biol Chem 1997;272:21037-44
38. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-58
39. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 1997;272:22987-90
40. Huang X, Atwood CS, Moir RD, et al. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J Biol Chem 1997;272:26464-70
41. Watson DJ, Lander AD, Selkoe DJ. Heparin-binding properties of the amyloidogenic peptides Aβ and amylin. Dependence on aggregation state and inhibition by congo red. J Biol Chem 1997;272:31617-24
42. Permanne B, Ferez C, Soto C, Frangione B, Wisniewski T. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 1997;240:715-20
43. Grossi D, Lopez L, Martinez AJ. Mammillary bodies in Alzheimer's disease. Acta Neurol Scand 1989;80:41-45